WGS
The table below shows GeneDx Holdings Corp.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $33.28M | -$28.50M | -$180.15M | -$319.15M | -$190.43M | -$93.13M |
| Capital expenditure | $19.02M | $5.49M | $5.25M | $7.16M | $9.40M | $24.09M |
| Investing cash flow | -$61.52M | -$30.13M | -$43.73M | -$141.33M | -$20.79M | -$31.97M |
| Dividends paid | - | - | - | - |
GeneDx Holdings Corp. reported operating cash flow of $33.28M for fiscal year 2025. That is up 216.8% from -$28.50M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from -$18.73M (FY 2019) to $33.28M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $48.02M | $44.16M | $186.24M | $197.31M | $493.73M | $129.06M |